Jump to content

Daratumumab

From Wikipedia, the free encyclopedia

Daratumumab
Fab fragment of daratumumab (teal/green) binding CD38 (pale pink). From PDB entry 7DHA
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetCD38
Clinical data
Trade namesDarzalex, Darzalex SC
AHFS/Drugs.comMonograph
MedlinePlusa616002
License data
Pregnancy
category
  • AU: C
Routes of
administration		Intravenous, subcutaneous
ATC code
Legal status
Legal status
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC6466H9996N1724O2010S42
Molar mass145391.67 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Daratumumab, sold under the brand name Darzalex among others, is an anti-cancer monoclonal antibody medication. It binds to CD38,[6] which is overexpressed in multiple myeloma cells.[7] Daratumumab was originally developed by Genmab, but it is now being jointly developed by Genmab along with the Johnson & Johnson subsidiary Janssen Biotech, which acquired worldwide commercialization rights to the drug from Genmab.[8]

Daratumumab was granted breakthrough therapy drug status in 2013, for multiple myeloma. It was granted orphan drug status for multiple myeloma, diffuse large B cell lymphoma, follicular lymphoma, and mantle cell lymphoma.[9]

It is available in combination with hyaluronidase as daratumumab/hyaluronidase (brand name Darzalex Faspro).[10][11]

Medical uses

[edit]

In May 2018, the US Food and Drug Administration (FDA) approved daratumumab for use in combination with bortezomib, melphalan and prednisone to include the treatment of people with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.[12]

In the European Union it is indicated as monotherapy for the treatment of adults with relapsed and refractory multiple myeloma,[13] whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.[14]

Side effects

[edit]

Treatment of multiple myeloma with daratumumab potentially increases the patient's susceptibility to bacterial and viral infections, due to the killing of natural killer cells (which are the main innate immune system defense against virus).[15] Daratumumab frequently causes human cytomegalovirus (CMV) reactivation by an unknown mechanism.[16] Injection related reactions (inflammation-like) are also common.[17]

Interactions

[edit]

With blood compatibility testing

[edit]

Daratumumab can also bind to CD38 present on red blood cells and interfere with routine testing for clinically significant antibodies. People will show a panreactive antibody panel, including a positive auto-control, which tends to mask the presence of any clinically significant antibodies. Treatment of the antibody panel cells with dithiothreitol (DTT) and repeating testing will effectively negate the binding of daratumumab to CD38 on the red blood cell surface; however, DTT also inactivates/destroys many antigens on the red blood cell surface by disrupting disulfide bonds. The only antigen system affected that is associated with common, clinically significant antibodies is Kell, making crossmatch testing with K-negative RBCs a reasonable alternative when urgent transfusion is indicated.[18] It is therefore advisable to do a baseline antibody screen and Rh & Kell phenotyping (type and screen) before starting the therapy. If antibody screen is negative, proceed with phenotype matched transfusions during therapy. If antibody screen is positive, give specific antigen negative blood. The incompatibility may persist for up to 6 months after stopping the medicine. Furthermore, blood transfusion centers should be routinely notified when sending such a sample.

With flow cytometry testing

[edit]

Daratumumab can also interfere with flow cytometric evaluation of multiple myeloma, causing an apparent lack of plasma cells.[19]

Pharmacology

[edit]

Mechanism of action

[edit]

Daratumumab is an IgG1k monoclonal antibody directed against CD38. CD38 is overexpressed in multiple myeloma cells. Daratumumab binds to a different CD38 epitope amino-acid sequence than does the anti-CD38 monoclonal antibody isatuximab.[20] Daratumumab binds to CD38, causing cells to apoptose via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, inhibition of mitochondrial transfer or antibody-dependent cellular phagocytosis.[21][22][23][24]

These effects are dependent upon fragment crystallizable region immune effector mechanisms.[25] Antibody-dependent cellular cytotoxicity is by means of natural killer cells.[26]

Unlike isatuximab which causes apoptosis directly, daratumumab only induces apoptosis indirectly.[25]

Multiple myeloma cells with higher levels of CD38 show greater daratumumab-mediated cell lysis than cells with low CD38 expression.[27] CD38 enzyme results in the formation of the immunosuppressive substance adenosine, so eliminating CD38-containing cells increases the ability of the immune system to eliminate cancer.[21]

History

[edit]

Encouraging preliminary results were reported in June 2012, from a Phase I/II clinical trial in relapsed multiple myeloma participants.[28] Updated trial results presented in December 2012, indicate daratumumab is continuing to show promising single-agent anti-myeloma activity.[29] A 2015 study compared monotherapy 8 and 16 mg/kg at monthly to weekly intervals.[7]

Daratumumab was given priority review status by the US Food and Drug Administration (FDA) for multiple myeloma as a combination therapy (second line).[23]

Daratumumab phase III trials for multiple myeloma show great promise in combination therapy with lenalidomide and dexamethasone,[30] as well as with bortezomib and dexamethasone.[31][needs update]

In November 2015, the US Food and Drug Administration (FDA) approved daratumumab for treatment of multiple myeloma in people who had received at least three prior therapies.[32][33] In May 2016 daratumumab was also conditionally approved by the European Medicines Agency for treatment of multiple myeloma.[34]

In November 2016, the FDA approved daratumumab in combination with lenalidomide or bortezomib and dexamethasone for the treatment of people with multiple myeloma who have received at least one prior therapy.[35]

The European Commission granted a marketing authorisation in May 2016.[36]

References

[edit]
  1. ^ "Prescription medicines: registration of new chemical entities in Australia, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 9 April 2023.
  2. ^ "Prescription medicines and biologicals: TGA annual summary 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 31 March 2024.
  3. ^ "Health Canada New Drug Authorizations: 2016 Highlights". Health Canada. 14 March 2017. Retrieved 7 April 2024.
  4. ^ "Darzalex SC Product information". Health Canada. 12 August 2020. Retrieved 24 June 2024.
  5. ^ "Darzalex- daratumumab injection, solution, concentrate Darzalex IV- daratumumab injection, solution, concentrate". DailyMed. Retrieved 18 December 2021.
  6. ^ World Health Organization (2009). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 101" (PDF). WHO Drug Information. 23 (2). Archived from the original (PDF) on 17 December 2010.
  7. ^ a b Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, et al. (September 2015). "Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma". The New England Journal of Medicine. 373 (13): 1207–1219. doi:10.1056/NEJMoa1506348. hdl:1874/331934. PMID 26308596.
  8. ^ "Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab". Janssen Biotech. Retrieved 31 January 2013.
  9. ^ "Daratumumab Receives Breakthrough Therapy Designation from US Food and Drug Administration". Genmab A/S. 1 May 2013. Archived from the original on 13 January 2017. Retrieved 10 January 2017.
  10. ^ "FDA approves daratumumab and hyaluronidase-fihj for multiple myeloma". U.S. Food and Drug Administration (FDA) (Press release). 1 May 2020. Retrieved 1 May 2020. Public Domain This article incorporates text from this source, which is in the public domain.
  11. ^ "Genmab Announces U.S. FDA Approval of Subcutaneous Formulation of Daratumumab, Darzalex Faspro (daratumumab and hyaluronidase-fihj), for the Treatment of Patients with Multiple Myeloma" (Press release). Genmab. 1 May 2020. Retrieved 1 May 2020 – via GlobeNewswire.
  12. ^ "FDA approves Darzalex for newly diagnosed, transplant-ineligible multiple myeloma". www.healio.com. Retrieved 8 May 2018.
  13. ^ Vincent L, Gras L, Ceballos P, Finke J, Passweg J, Harel S, et al. (March 2022). "Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT" (PDF). Bone Marrow Transplantation. 57 (3): 499–501. doi:10.1038/s41409-021-01560-y. PMID 35013536. S2CID 245861546.
  14. ^ "SUMMARY OF PRODUCT CHARACTERISTICS" (PDF). www.ema.europa.eu. Retrieved 4 June 2019.
  15. ^ Nahi H, Chrobok M, Gran C, Lund J, Gruber A, Gahrton G, et al. (2019). "Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma". PLOS ONE. 14 (2): e0211927. Bibcode:2019PLoSO..1411927N. doi:10.1371/journal.pone.0211927. PMC 6374018. PMID 30759167.
  16. ^ Nakagawa R, Onishi Y, Kawajiri A, Onodera K, Furukawa E, Sano S, et al. (August 2019). "Preemptive therapy for cytomegalovirus reactivation after daratumumab-containing treatment in patients with relapsed and refractory multiple myeloma". Annals of Hematology. 98 (8): 1999–2001. doi:10.1007/s00277-019-03645-7. PMID 30824957. S2CID 71146150.
  17. ^ Jain A, Ramasamy K (September 2020). "Evolving Role of Daratumumab: From Backbencher to Frontline Agent". Clinical Lymphoma, Myeloma & Leukemia. 20 (9): 572–587. doi:10.1016/j.clml.2020.03.010. PMID 32331971. S2CID 216131042.
  18. ^ Chapuy CI, Nicholson RT, Aguad MD, Chapuy B, Laubach JP, Richardson PG, et al. (June 2015). "Resolving the daratumumab interference with blood compatibility testing". Transfusion. 55 (6 Pt 2): 1545–1554. doi:10.1111/trf.13069. PMID 25764134.
  19. ^ Perincheri S, Torres R, Tormey CA, Smith BR, Rinder HM, Siddon AJ (2 December 2016). "Daratumumab Interferes with Flow Cytometric Evaluation of Multiple Myeloma". Blood. 128 (22): 5630. doi:10.1182/blood.V128.22.5630.5630. ISSN 0006-4971.
  20. ^ Dhillon S (June 2020). "Isatuximab: First Approval". Drugs. 80 (9): 905–912. doi:10.1007/s40265-020-01311-1. PMID 32347476. S2CID 216597315.
  21. ^ a b Konen JM, Fradette JJ, Gibbons DL (December 2019). "The Good, the Bad and the Unknown of CD38 in the Metabolic Microenvironment and Immune Cell Functionality of Solid Tumors". Cells. 9 (1): 52. doi:10.3390/cells9010052. PMC 7016859. PMID 31878283.
  22. ^ Roccatello D, Fenoglio R, Sciascia S, Naretto C, Rossi D, Ferro M, et al. (June 2020). "CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond". International Journal of Molecular Sciences. 21 (11): 4129. doi:10.3390/ijms21114129. PMC 7312896. PMID 32531894.
  23. ^ a b "Daratumumab - Janssen Biotech - AdisInsight". adisinsight.springer.com.
  24. ^ Mistry JJ, Moore JA, Kumar P, Marlein CR, Hellmich C, Pillinger G, et al. (February 2021). "Daratumumab inhibits acute myeloid leukaemia metabolic capacity by blocking mitochondrial transfer from mesenchymal stromal cells". Haematologica. 106 (2): 589–592. doi:10.3324/haematol.2019.242974. PMC 7849566. PMID 32193250.
  25. ^ a b Martin TG, Corzo K, Chiron M, Velde HV, Abbadessa G, Campana F, et al. (November 2019). "Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab". Cells. 8 (12): 1522. doi:10.3390/cells8121522. PMC 6953105. PMID 31779273.
  26. ^ Nooka AK, Kaufman JL, Hofmeister CC, Joseph NS, Heffner TL, Gupta VA, et al. (July 2019). "Daratumumab in multiple myeloma". Cancer. 125 (14): 2364–2382. doi:10.1002/cncr.32065. PMID 30951198.
  27. ^ Franssen LE, Stege CA, Zweegman S, van de Donk NW, Nijhof IS (April 2020). "Resistance Mechanisms Towards CD38-Directed Antibody Therapy in Multiple Myeloma". Journal of Clinical Medicine. 9 (4): 1195. doi:10.3390/jcm9041195. PMC 7230744. PMID 32331242.
  28. ^ "ASCO: Drug Shows Promise in Myeloma". MedPage Today.
  29. ^ "Daratumumab Continues To Show Promise For Relapsed/Refractory Myeloma Patients (ASH 2012)". The Myeloma Beacon. Retrieved 31 January 2013.
  30. ^ Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. (October 2016). "Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma". The New England Journal of Medicine. 375 (14): 1319–1331. doi:10.1056/NEJMoa1607751. PMID 27705267.
  31. ^ Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, et al. (August 2016). "Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma". The New England Journal of Medicine. 375 (8): 754–766. doi:10.1056/NEJMoa1606038. hdl:11343/240283. PMID 27557302.
  32. ^ "Daratumumab Approved for Multiple Myeloma in US". Medscape.
  33. ^ "Darzalex New FDA Drug Approval". CenterWatch. Archived from the original on 5 August 2019. Retrieved 4 June 2019.
  34. ^ "Janssen's Single-Agent Darzalex (daratumumab) Approved by European Commission for Treatment of Multiple Myeloma (MM)" (Press release). 23 May 2016. Retrieved 23 May 2016 – via Business Wire.
  35. ^ "Daratumumab (Darzalex)". U.S. Food and Drug Administration (FDA). 9 February 2019.
  36. ^ "An overview of Darzalex and why it is authorised in the EU" (PDF). www.ema.europa.eu. 2018. Retrieved 4 June 2019.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Daratumumab&oldid=1239255915"